Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$5.95 - $15.79 $202,186 - $536,559
33,981 New
33,981 $535,000
Q1 2023

May 15, 2023

BUY
$5.62 - $11.51 $91,341 - $187,072
16,253 Added 119.39%
29,866 $173,000
Q4 2022

Feb 14, 2023

SELL
$2.32 - $10.97 $28,570 - $135,095
-12,315 Reduced 47.5%
13,613 $108,000
Q3 2022

Nov 14, 2022

BUY
$3.09 - $9.21 $80,117 - $238,796
25,928 New
25,928 $82,000
Q3 2022

Nov 14, 2022

BUY
$3.09 - $9.21 $80,117 - $238,796
25,928 New
25,928 $82,000
Q2 2022

Aug 16, 2022

SELL
$5.7 - $10.33 $243,760 - $441,762
-42,765 Closed
0 $0
Q1 2022

May 17, 2022

BUY
$4.41 - $22.5 $188,593 - $962,212
42,765 New
42,765 $301,000

Others Institutions Holding ICVX

About Icosavax, Inc.


  • Ticker ICVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,885,200
  • Description
  • Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...
More about ICVX
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.